Locally advanced Urothelial Carcinoma

Drug	Drug Name	Drug Description
DB11945	Avelumab	An anti-PD-L1 monoclonal antibody used to treat metastatic merkel cell carcinoma, metastatic urothelial carcinoma, or renal cell carcinoma.
DB09035	Nivolumab	A PD-1 blocking antibody used to treat melanoma, non small-cell lung cancer, renal cell cancer, head and neck cancer, and Hodgkin lymphoma.
DB09037	Pembrolizumab	A PD-1 blocking antibody used to treat various types of cancer, including metastatic melanoma, non small-cell lung cancer, cervical cancer, head and neck cancer, and Hodgkin's lymphoma.

Drug	Drug Name	Target	Type
DB11945	Avelumab	Programmed cell death 1 ligand 1	target
DB09035	Nivolumab	Programmed cell death protein 1	target
DB09035	Nivolumab	Programmed cell death 1 ligand 1	target
DB09037	Pembrolizumab	Programmed cell death protein 1	target
DB09037	Pembrolizumab	Programmed cell death 1 ligand 1	target

Drug	Drug Name	Phase	Status	Count
DB05015	Belinostat	1	Recruiting	1
DB08875	Cabozantinib	1	Recruiting	1
DB00531	Cyclophosphamide	1	Recruiting	1
DB11714	Durvalumab	1	Recruiting	1
DB13007	Enfortumab vedotin	1	Recruiting	2
DB12147	Erdafitinib	1	Recruiting	1
DB09037	Pembrolizumab	1	Recruiting	2
DB00020	Sargramostim	1	Recruiting	1
DB09143	Sonidegib	1	Recruiting	1
DB08871	Eribulin	1 / 2	Active Not Recruiting	1
DB01175	Escitalopram	1 / 2	Recruiting	1
DB09037	Pembrolizumab	1 / 2	Active Not Recruiting	1
DB09037	Pembrolizumab	1 / 2	Recruiting	1
DB11942	Selinexor	1 / 2	Recruiting	1
DB12887	Tazemetostat	1 / 2	Active Not Recruiting	1
DB11945	Avelumab	2	Recruiting	1
DB13007	Enfortumab vedotin	2	Recruiting	1
DB09035	Nivolumab	2	Recruiting	3
DB09037	Pembrolizumab	2	Recruiting	2
DB00571	Propranolol	2	Recruiting	1
DB14851	Relatlimab	2	Recruiting	1
DB11595	Atezolizumab	3	Active Not Recruiting	1
DB11945	Avelumab	3	Active Not Recruiting	1
DB11714	Durvalumab	3	Active Not Recruiting	1
DB09035	Nivolumab	3	Active Not Recruiting	1
DB09037	Pembrolizumab	3	Active Not Recruiting	2
DB12147	Erdafitinib	Not Available	Terminated	1